Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionMan Group plc
Latest Disclosed Ownership315,212 shares
Latest Disclosed Value $ 243,545,399
Man Group plc reports 44.52% increase in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On May 15, 2026 - Man Group plc filed a 13F-HR form disclosing ownership of 315,212 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $243,545,399 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 218,112 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of 44.52% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 315,212 97,100 44.52 243,545 44.66 0.4418
2026-02-17 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 218,112 -53,595 -19.73 168,354 10.20 0.2862
2025-11-14 2025-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 271,707 195,724 257.59 152,773 282.97 0.2657
2025-08-14 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 75,983 40,397 113.52 39,891 76.75 0.0760
2025-05-15 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 35,586 -558 -1.54 22,570 -12.34 0.0572
2025-02-14 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 36,144 -24,377 -40.28 25,746 -59.53 0.0677
2024-11-14 2024-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 60,521 8,777 16.96 63,622 16.99 0.1657
2024-08-14 2024-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 51,744 -56,728 -52.30 54,384 -47.91 0.1373
2024-05-15 2024-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 108,472 14,912 15.94 104,403 27.05 0.2632
2024-02-14 2023-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 93,560 82,173 147.24 0.2288
2023-11-14 2023-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 33,237 -60.34 0.1030
2023-08-14 2023-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 116,636 83,808 238.66 0.2585
2023-05-15 2023-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 24,747 -55.52 0.0880
2023-02-14 2022-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 77,120 57,473 292.53 55,641 311.12 0.1995
2022-11-14 2022-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 19,647 13,534 -40.61 0.0628
2022-08-15 2022-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 22,788 8.87 0.0966
2022-05-16 2022-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 29,970 -117,219 -79.64 20,931 -77.48 0.0728
2022-02-14 2021-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 147,189 66,819 83.14 92,953 91.12 0.2989
2021-11-15 2021-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 80,370 -28,583 -26.23 48,637 -20.08 0.1706
2021-08-16 2021-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 108,953 -11,314 -9.41 60,855 6.95 0.2143
2021-05-17 2021-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 120,267 74,920 165.21 56,903 159.74 0.2502
2021-02-16 2020-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 45,347 17,041 60.20 21,908 38.26 0.0962
2020-11-16 2020-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 28,306 -5,658 -16.66 15,845 -25.20 0.0623
2020-08-14 2020-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 33,964 3,280 10.69 21,182 41.37 0.1068
2020-05-15 2020-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 30,684 2,363 8.34 14,983 40.91 0.0971
2020-02-18 2019-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 28,321 13,695 93.63 10,633 162.03 0.0350
2019-11-14 2019-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 14,626 -2,383 -14.01 4,058 -23.79 0.0151
2019-08-14 2019-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 17,009 12,980 322.16 5,325 221.95 0.0192
2019-05-15 2019-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 4,029 -1,647 -29.02 1,654 -21.94 0.0063
2019-02-14 2018-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 5,676 -490 -7.95 2,119 -14.93 0.0094
2018-11-14 2018-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 6,166 -74 -1.19 2,491 15.75 0.0091
2018-08-14 2018-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 6,240 -41 -0.65 2,152 -0.51 0.0089
2018-05-15 2018-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 6,281 6,281 2,163 0.0099
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.